Areview On Rheumatoid Arthiritis
DOI:
https://doi.org/10.22270/ajprd.v10i6.1200Keywords:
Rheumatoid arthritis, autoimmune disease, chronotherapy, DMARDs.Abstract
Rheumatoid arthritis is a persistent, painful inflammatory condition characterized by serious destruction of the bone marrow and cartilage in the joints. It can also affect the body as a whole, including the tissues, leading to disorders of the heart, lungs, nervous system, and eyes. It is an extremely painful inflammatory condition that significantly limits movement due to pain and joint deterioration. Systemic disease rheumatoid arthritis usually affects tissues that constrict. Age, race, inheritance, aberrant immunological functioning, and stress are risk factors. Early rheumatoid arthritis appears to have a unique cytokine profile for the production of interleukin-4, 13, and 15,52, which later show in chronic rheumatoid arthritis. The main objectives of rheumatoid arthritis treatment are to minimize pain and stop or slow the disease's progression. Therefore, early disease detection and correct diagnosis and treatment are crucial. Low-dose GCs combined with Awards are a safe and effective therapy choice for radiographic progression, symptom reduction, and high rates of clinical remission.
Downloads
References
2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. New England Jour-nal of Medicine. 2011 Dec 8;365(23):2205-19.
3. Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, Zhang Y, Damja-nov N, Friedman A, Othman AA, Camp HS. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. The Lancet. 2019 Jun 8;393(10188):2303-11.
4. Genovese MC. Biologic therapies in clinical development for the treatment of rheu-matoid arthritis. JCR: Journal of Clinical Rheumatology. 2005 Jun 1;11(3):S45-54.
5. Johnston SS, Turpcu A, Shi N, Fowler R, Chu BC, Alexander K. Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis. InSeminars in arthritis and rheumatism 2013 Aug 1 (Vol. 43, No. 1, pp. 39-47). WB Saunders.
6. Heliövaara M, Aho K, Aromaa A, Knekt P, Reunanen A. Smoking and risk of rheu-matoid arthritis. The Journal of rheumatology. 1993 Nov 1;20(11):1830-5.
7. Van Schaardenburg D, Hazes JM, De Boer A, Zwinderman AH, Meijers KA, Breed-veld FC. Outcome of rheumatoid arthritis in relation to age and rheumatoid factor at diagnosis. The Journal of rheumatology. 1993 Jan 1;20(1):45-52.
8. Wallace CA, Levinson JE. Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheumatic diseases clinics of North America. 1991 Nov 1;17(4):891-905.
9. Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. Ge-netic and environmental risk factors for rheumatoid arthritis. Best practice & research Clinical rheumatology. 2017 Feb 1;31(1):3-18.
10. Van de Sande MG, De Hair MJ, Van Der Leij C, Klarenbeek PL, Bos WH, Smith MD, Maas M, De Vries N, Van Schaardenburg D, Dijkmans BA, Gerlag DM. Differ-ent stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Annals of the rheumatic diseases. 2011 May 1;70(5):772-7.
11. Al-Rubaye AF, Kadhim MJ, Hameed IH. Rheumatoid Arthritis: History, Stages, Epi-demiology, Pathogenesis, Diagnosis and Treatment. International Journal of Toxico-logical and Pharmacological Research. 2017;9(2):145-55.
12. Gaffo A, Saag KG, Curtis JR. Treatment of rheumatoid arthritis. American journal of health-system pharmacy. 2006 Dec 15;63(24):2451-65.
13. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathologi-cal mechanisms and modern pharmacologic therapies. Bone research. 2018 Apr 27;6(1):1-4.
14. Combe B. Progression in early rheumatoid arthritis. Best Practice & Research Clini-cal Rheumatology. 2009 Feb 1;23(1):59-69.
15. Breedveld FC, Dijkmans BA. Differential therapy in early and late stages of rheuma-toid arthritis. Current opinion in rheumatology. 1996 May 1;8(3):226-9.
16. Dekkers J, Toes RE, Huizinga TW, van der Woude D. The role of anticitrullinated protein antibodies in the early stages of rheumatoid arthritis. Current opinion in rheumatology. 2016 May 1;28(3):275-81.
17. Stanaszek WF, Carlstedt BC. Rheumatoid Arthritis: Pathophysiology. Journal of Pharmacy Practice. 1999 Aug;12(4):282-92.
18. Sailaja AK. An overall review on rheumatoid arthritis. Journal of Current Pharma Research. 2014;4(2):1138.
19. Kung TN, Bykerk VP. Detecting the earliest signs of rheumatoid arthritis: symptoms and examination. Rheumatic Disease Clinics. 2014 Nov 1;40(4):669-83.
20. Combe B. Early rheumatoid arthritis: strategies for prevention and management. Best practice & research Clinical rheumatology. 2007 Feb 1;21(1):27-42.
21. Heidari B. Rheumatoid Arthritis: Early diagnosis and treatment outcomes. Caspian journal of internal medicine. 2011;2(1):161.
22. Pincus T, Sokka T. Laboratory tests to assess patients with rheumatoid arthritis: ad-vantages and limitations. Rheumatic diseases clinics of North America. 2009 Nov 1;35(4):731-4
23. Flaishon L, Hart G, Zelman E, Moussion C, Grabovsky V, Lapidot Tal G, Feigelson S, Margalit R, Harmelin A, Avin-Wittenberg T, Shoseyov D. Anti-inflammatory ef-fects of an inflammatory chemokine: CCL2 inhibits lymphocyte homing by modula-tion of CCL21-triggered integrin-mediated adhesions. Blood, The Journal of the American Society of Hematology. 2008 Dec 15;112(13):5016-25.
24. Majithia V, Geraci SA. Rheumatoid arthritis: diagnosis and management. The American journal of medicine. 2007 Nov 1;120(11):936-9.
25. Suresh E. Diagnosis of early rheumatoid arthritis: what the non-specialist needs to know. Journal of the Royal Society of Medicine. 2004 Sep;97(9):421-4.
26. To H. Chronotherapy for rheumatoid arthritis: current perspectives. ChronoPhysiolo-gy and Therapy. 2016 Aug 3;6:47-53
27. Jacobs JW, Bijlsma JW. Modified release prednisone in patients with rheumatoid arthritis. Annals of the rheumatic diseases. 2010 Jul 1;69(7):1257-9.
28. Kowanko IC, Pownall R, Knapp MS, Swannell AJ, Mahoney PG. Time of day of prednisolone administration in rheumatoid arthritis. Annals of the Rheumatic Diseas-es. 1982 Oct 1;41(5):447-52..
29. Cutolo M. Glucocorticoids and chronotherapy in rheumatoid arthritis. RMD open. 2016 Mar 1;2(1):e000203.
30. Paolino S, Cutolo M, Pizzorni C. Glucocorticoid management in rheumatoid arthritis: morning or night low dose?.Reumatologia/Rheumatology. 2017 Aug 31;55(4):189-97.
Published
How to Cite
Issue
Section
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.